TP53 and cancer: While current drug development is focusing on antibody drug-conjugates with cytotoxic payloads like doxorubicin or antimitotic agents like maytansinol, these may prove to be ineffective because their toxic payloads do not work in p53-null or mutant cancers (Edwards et al., 2011; Sun et al., 2016).